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Hospitalized patients with left ventricular failure (LVF) are at high risk for potential drug-drug 
interactions (pDDIs) and its related adverse effects owing to multiple risk factors such as old age, 
comorbidities and polypharmacy. This cross-sectional study conducted in two tertiary care hospitals 
aim to identify frequency, levels and predictors of pDDIs in LVF patients. Data about patients’ 
demographic, hospital stay, medication therapy, sign/symptoms and laboratory test results were 
collected for 385 patients with LVF. Micromedex Drug-Reax® was used to screen patients’ medication 
profiles for pDDIs. Overall prevalence and severity-wise prevalence of pDDIs were identified. Chi-
square test was performed for comparative analysis of various variables. Logistic regression was 
applied to determine the odds-ratios (OR) for predictors of pDDIs. The prevalence of pDDIs was 
96.4% (n=371). Overall 335 drug-interacting pairs were detected, which were presented in a total 
of 2870 pDDIs. Majority of pDDIs were of major- (48.9%) and moderate-severity (47.5%). Logistic 
regression analysis shows significant association of >6 all types of pDDIs with >12 drugs as compared 
with <8 drugs (OR=16.5; p=<0.001). Likewise, there was a significant association of >4 major-
pDDIs with men as compared with female (OR=1.9; p=0.007) and >12 drugs as compared with <8 
drugs (OR=10.9; p=<0.001). Hypotension (n=57), impaired renal function (23) and increased blood 
pressure (22) were the most frequent adverse outcomes associated with pDDIs. This study shows high 
prevalence of pDDIs in LVF patients. Majority of pDDIs were of major- and moderate-severity. Male 
patients and those prescribed greater number of medicines were more exposed to major-pDDIs.
Keywords: Left ventricular failure. Heart diseases. Potential drug-drug interactions. Drug 
interactions. Patients safety. Rational drug use.
INTRODUCTION
Left Ventricular Failure (LVF) represents a subset 
of heart failure (HF) (Rosenkranz et al., 2016). HF is 
recognized as a major health concern (Go et al., 2014) 
because of severely frequent adverse health outcomes 
and its extensive financial implications (Sanchez-
Fidalgo et al., 2017). HF affects around 2% of the adult 
population worldwide, (Metra, Teerlink, 2017) making 
it a leading cause of hospitalization (Alvarez et al., 
2017). Hospitalized patients with LVF (Rosenkranz 
et al., 2016) are at high risk for developing potential 
drug-drug interactions (pDDIs) (Bykov, Gagne, 
2017) owing to its underlying risk factors, advancing 
age, multiple comorbidities (Alvarez et al., 2017), 
polypharmacy (Ismail et al., 2017; Stough, Patterson, 
2017) and/or combinations of these factors (Meid 
et al., 2017).
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Pharmacotherapy is the most common mode of 
therapeutic management of the LVF. This comprises 
of a complex regimen (polypharmacy); beta-blockers, 
angiotensin converting enzyme inhibitors, diuretics, 
ionotropic agents, the aldosterone antagonist and more 
recently, the angiotensin receptor neprilysin inhibitors 
(Stough, Patterson, 2017), is the currently widely 
applied strategy of treatment (Stough, Patterson, 2017). 
The published data demonstrated that LVF trumps 
polypharmacy among other disorders like diabetes, 
chronic obstructive pulmonary disease (COPD) and 
asthma in community (Ledwidge et al., 2004).
Polypharmacy is a major contributing risk factor 
for drug-drug interactions (DDIs). The incidence 
of DDIs in patients with HF ranges from 13% for 2 
drugs to 82% for ≥7 drugs (Roblek et al., 2016). About 
16-26% of adverse drug reactions (ADRs) related 
hospital admissions in patients with HF are due to 
DDIs (Roblek et al., 2016; Roblek et al., 2014) which 
leads to increased hospitalization, excessive treatment 
cost and impaired quality of life (Roblek et al., 2014). 
DDIs may either surge to increased toxicity or reduced 
therapeutic efficacy (Cruciol-Souza, Thomson, 2006b; 
Moura et al., 2012). 
Few studies have addressed this issue in HF; 
however, these studies have several gaps and limitations 
(Roblek et al., 2014; Straubhaar, Krahenbuhl, Schlienger, 
2006). A Slovenian study primarily focused at patients 
with HF and COPD addressed this issue, however it 
was not exclusively performed in patients with LVF. 
Moreover, it merely reported the prevalence of pDDIs 
(Roblek et al., 2014). Whereas, another study from 
Switzerland, although was exclusively performed in HF 
patients, but it only reported the prevalence and nature 
of pDDIs (Straubhaar, Krahenbuhl, Schlienger, 2006). 
Therefore, there is a need for explicit work in patients 
with LVF particularly in developing countries, including 
Pakistan because of scarce literature.
An appraisal of the literature reveals no research 
that poses a specific insight into all aspects of pDDIs 
in patients with LVF. These aspects include predictors 
of pDDIs, documentation levels suggesting support 
of pDDIs through literature, understanding of the 
widespread interacting drug pairs and assessment of 
associated clinical relevance based on patients’ clinical 
characteristics (sign/symptoms, blood pressure) and 
related laboratory/diagnostic tests (blood urea nitrogen, 
serum creatinine, serum potassium, serum sodium, 
prothrombin time (PT), activated partial thromboplastin 
time (APTT), international normalized ratio (INR), 
hemoglobin and platelet concentration), which can 
optimize the quality of prescribing in patients with LVF. 
Forgoing in view, we aim to identify the frequency, 
levels and predictors of pDDIs along with its associated 
clinical relevance. Moreover, we aim to develop a list of 
most frequent pDDIs in hospitalized patient with LVF. 
PATIENTS AND METHODS
Setting and Design
This cross-sectional retrospective study was 
performed in the cardiology wards of two major tertiary 
care hospitals of a provincial capital. This study included 
hospitalized patients’ medication profiles (n=385) 
diagnosed with LVF, > 18 years of age and either gender, 
for a period of one-year from May 2015 to April 2016. 
Patients’ profiles lacking relevant data required for this 
study were excluded.
Ethical Considerations
This study was approved by the institutional ethics 
committee.
Data collection
Permission was obtained from the hospitals’ 
administration in order to access patients’ medication 
profiles. Data regarding patient’s demographic, hospital 
admission, medication therapy, signs, symptoms and 
laboratory/diagnostic test results were collected.
Data analysis
Micromedex Drug-Reax® (Micromedex, 2018) was 
used to screen patients’ medication profile for pDDIs. 
It is an online screening tool in which all prescribed 
medications are entered, and in return a list of all pDDIs is 
generated as an output, based on the most recent available 
literature on drug interactions. We used Micromedex 
Drug-Reax® because of its well-documented precision, 
completeness, sensitivity and specificity (Vonbach et 
al., 2008). This drug interaction screening tool classifies 
pDDIs on the basis of their severity and the available 
scientific evidence (Roblek et al., 2015). The severity-
levels of pDDIs and their description is as follows:
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Contraindicated: The co-prescription of the drug pair 
is not advised owing its proven risk.
Major: The co-prescription of the drug pair may lead to 
life-threating adverse events, requiring prompt medical 
intervention.
Moderate: The co-prescription of the drug pair may 
deteriorate patient’s clinical well-being, requiring 
prompt changes in medication therapy.
Minor: The co-prescription of the drug pair may result 
in limited clinically relevant untoward events, however 
no major modifications in the drug therapy is required.
Furthermore, the pDDIs are also categorized into the 
following groups based on available scientific evidence:
Excellent: Interaction arising from co-prescription of 
the drug pair has been confirmed by controlled studies.
Good: Interaction arising from co-prescription of the 
drug pair has been suggested by studies, but well-
controlled studies are scarce.
Fair: Interaction arising from co-prescription of the drug 
pair has poor documentary evidence for the presence of 
any clinically relevant untoward effect.
Statistical Analysis
Quantitative variables like patient’s age, hospital stay, 
number of prescribed medications and number of pDDIs 
per patient are presented as median and interquartile 
range (IQR). The pDDIs are classified categorically with 
regard to their frequencies and percentages. However, 
gender, prevalence of pDDIs, number of pDDIs per 
patient, severity levels and documentation levels are 
presented in the form of frequencies and percentages. 
Chi-square test was performed to identify the differences 
among patients’ characteristics with >6 all types of 
pDDIs and >4 major-pDDIs. Logistic regression analysis 
was applied in order to identify associations of presence 
of >6 pDDIs with patients’ gender, age, hospital stay and 
prescribed medications. Moreover, association of >4 
major-pDDIs exposure to above mentioned variables was 
also identified. Exposure to >6 pDDIs of any severity and 
exposure to >4 major-DDIs were the dependent variables 
in the model. Variables that were taken as predictors of 
pDDIs include gender, age, hospital stay and number of 
prescribed medications. For each predictor, odds ratio 
(OR) and 95% confidence interval (CI) were determined. 
Initially univariate logistic regression analysis was carried 
out followed by the performance of multivariate analysis 
for the variables with significant univariate p-values. 
In this study, p-value of 0.05 or less was considered 
statistically significant. SPSS-v21 was used for statistical 
analysis. The clinical relevance of the most frequent (top 
ten drug interacting pairs) was identified on the basis of 
signs/symptoms and laboratory test results. 
RESULTS
Patients’ characteristics
Of total 385 patients, 52.5% were female and 
47.5% were male. The median age was 60 years, where 
majority of patients (64.2%) had >55 years of age. The 
median hospital stay was 4 days with high proportion 
of patients (42.9%) having hospital stay of 4-6 days, 
followed by 41% patients with ≤3 days of hospital stay. 
Patients received a median of 11 drugs, 40.5% patients 
received 9-12 drugs, followed by >12 drugs prescribed 
to 39.5% patients as shown in Table I.
TABLE I - General characteristics of study subjects
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TABLE I - General characteristics of study subjects
Characteristics Patients: n (%)
Prescribed medications





IQR = Interquartile range.
Frequencies of pDDIs
Frequencies of potential drug-drug interactions 
are presented in Figure 1. Of total 385 patients, 96.4% 
patients had one or more pDDI(s). Nearly 91% patients 
had at least one major-pDDI, similarly 91% had at least 
one moderate-pDDI. Whereas, 13.5% patients had at 
least one minor-pDDI and 3.4% patients had one or 
more contraindicated pDDI(s). Majority of patients had 
pDDIs with good (90.1%) and fair (90.1%) documented 
evidence. While, 40% patients had pDDIs with excellent 
documented evidence. Moreover, majority of patients 
(51.2%) had >6 pDDIs, followed by 29.1% patients 
having 4-6 pDDIs. While, only 3.6% patients had no 
pDDIs.
FIGURE 1 - Frequencies of pDDIs = Potential drug-drug interactions.
Number of pDDIs per patient: Median = 7 (Inter quartile range = 4-10)
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Levels of pDDIs
Figure 2 illustrates levels of pDDIs. Overall 335 
drug interacting pairs were detected, which were 
presented in total of 2870 pDDIs. The identified pDDIs 
were categorized on the basis of severity-type and 
documented evidence. Of 2870 pDDIs, 1405 (48.9%) 
were of major-severity and 1365 (47.5%) were of 
moderate severity; whereas 47% and 44.9% were of 
good and fair documented evidence, respectively. Of the 
335 drug interacting pairs 177 (52.8%) were of major-
severity, while 133 (39.7%) were of moderate-severity, 
whereas, 184 (54.9%) and 112 (33.4%) were of fair and 
good documented evidence, respectively.
FIGURE 2 - Levels of identified pDDIs.
pDDIs = Potential drug-drug interactions. 
Predictors of pDDIs 
Table II presents exposure to >6 all types of pDDIs 
and >4 major-pDDIs stratified with respect to patients’ 
characteristics such as gender, age, hospital stay and 
prescribed medications along with their comparative 
analysis. Significant differences were observed for 
prescribed medicines with >6 all types of pDDIs. 
Whereas, differences between gender, age and hospital 
stay were not significant. On the other hand, significant 
differences were estimated for gender and prescribed 
medications with >4 major-pDDIs. While, no significant 
differences were present with age and hospital stay. 
In addition, significant differences were noted with 
number of prescribed medications for excellent and 
good documentation.
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TABLE II - Exposure to potential drug-drug interactions and documentation levels, stratified according to patients’ characteristics 
Variables












Absent Present Absent Present Absent Present Absent Present
Gender
Male 89 (23.1%) 94 (24.4) NS 117 (30.4) 66 (17.1) 0.008 112 (29.1) 71 (18.4) NS 13 (3.4) 170 (44.2) 0.083
Female 99 (25.7) 103 (26.8) 154 (40) 48 (12.5) 119 (30.9) 83 (21.6)  25 (6.5) 177 (46)  
Age (Years)
≤ 40 14 (3.6) 11 (2.9) NS 19 (4.9) 6 (1.6) NS 18 (4.7) 7 (1.8) NS 1 (0.3) 24 (6.2) NS
41-55 48 (12.5) 65 (16.9) 82 (21.3) 31 (8.1) 63 (16.4) 50 (13)  9 (2.3) 104 (27)  
>55 126 (32.7) 121 (31.4) 170 (44.2) 77 (20) 150 (39) 97 (25.2)  28 (7.3) 219 (56.9)  
Hospital stay (Days)
≤ 3 85 (22.1) 73 (19) NS 117 (30.4) 41 (10.6) NS 103 (26.8) 55 (14.3) NS 14 (3.6) 144 (37.4) NS
4-6 79 (20.5) 86 (22.3) 113 (29.4) 52 (13.5) 91 (23.6) 74 (19.2)  19 (4.9) 146 (37.9)  
>6 24 (6.2) 38 (9.9) 41 (10.6) 21 (5.5) 37 (9.6) 25 (6.5)  5 (1.3) 57 (14.8)  
Prescribed medicines
≤ 8 64 (16.6) 13 (3.4) <0.001 71 (18.4) 6 (1.6) <0.001 59 (15.3) 18 (4.7) <0.001 15 (3.9) 62 (16.1) 0.006
9-12 85 (22.1) 71 (18.4) 120 (31.2) 36 (9.4) 105 (27.3) 51 (13.2)  13 (3.4) 143 (37.1)  
>12  39 (10.1) 113 (29.4) 80 (20.8) 72 (18.7) 67 (17.4) 85 (22.1)  10 (2.6) 142 (36.9)  
pDDIs = potential drug-drug interactions. 
Table III represents the results of univariate 
logistic regression analysis for exposure to >6 all 
types of pDDIs and >4 major-pDDIs. In comparison 
with ≤3 days of hospital stay, the risk of >6 all types 
of pDDIs increases by 1.8 times in patients with >6 
days of hospital stay (p=0.045). Similarly, the risk of 
>6 all types of pDDIs is 4.1 times higher in patients 
prescribed 9-12 drugs (p=<0.001) and 14.3 times 
higher in patients taking >12 drugs (p=<0.001) as 
compared with patients taking ≤8 drugs. Whereas, no 
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significant association was estimated for differences 
between gender and age groups. The risk of >4 major-
pDDIs is 1.8 times higher in male patients (p=0.009) 
as compared with female patients. Similarly, the risk 
increases by 3.6 times in patients prescribed 9-12 
drugs (p=0.007) and 10.6 times in patients prescribed 
>12 drugs (p=<0.001) as compared with ≤8 drugs. 
Logistic regression for pDDIs of good documentation 
showed significant association with 9-12 prescribed 
drugs (p=0.02) and >12 prescribed drugs (p=0.005), 
while, significant association was observed for pDDIs 
of excellent documentation with >12 prescribed drugs 
(p=<0.001).
The results of multivariate logistic regression 
analysis are presented in Table IV. In comparison 
with ≤8 prescribed drugs, the risk of >6 all types 
of pDDIs is 4.5 times higher in patients taking 9-12 
drugs (p=<0.001) and 16.5 times in patients taking 
>12 drugs (p=<0.001). Whereas, no significant 
association was observed between differences in 
hospital stay. For >4 major-pDDIs, the risk is 1.9 times 
higher in male patients (p=0.007) as compared with 
female patients. Similarly, the risk of >4 major-pDDIs 
is 3.5 times higher in patients prescribed 9-12 drugs 
(p=0.008) and 10.9 times in patients taking >12 drugs 
(p=<0.001) as compared with ≤8 drugs. Likewise, the 
odds ratios were significant for pDDIs of excellent 
documentation with >12 prescribed drugs (p=<0.001) 
and similarly for pDDIs of good documentation with 
>12 prescribed drugs (p=0.005).
TABLE III - Univariate logistic regression analysis based on exposure to >6 pDDIs, >4 Major-pDDIs and documentation levels
Variables
>6 pDDIs >4 Major-pDDIs Excellent pDDIs Good pDDIs
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Gender
Female Reference Reference Reference Reference
Male 1 0.7-1.5 0.9 1.8 1.2-2.8 0.009 0.9 0.6-1.4 0.6  1.8 0.9-3.7 0.09
Age (Years)
<40 Reference Reference Reference Reference
41-55 1.7 0.7-4.1 0.2 1.2 0.4-3.3 0.7 2 0.8-5.3 0.1  0.5 0.06-4 0.5
>55 1.2 0.5-2.8 0.6 1.4 0.6-3.7 0.5 1.7 0.7-4 0.3  0.3 0.04-2.5 0.3
Hospital stay (Days)
<3 Reference Reference Reference Reference
4-6 1.3 0.8-2 0.3 1.3 0.8-2.1 0.3 1.5 1-2.4 0.07  0.7 0.4-1.5 0.4
(continuing)
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TABLE III - Univariate logistic regression analysis based on exposure to >6 pDDIs, >4 Major-pDDIs and documentation levels
Variables
>6 pDDIs >4 Major-pDDIs Excellent pDDIs Good pDDIs
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
>6 1.8 1-3.4 0.045 1.5 0.8-2.8 0.2 1.3 0.7-2.3 0.4  1.1 0.4-3.2 0.8
Prescribed medicines
<8 Reference Reference Reference Reference
9-12 4.1 2.1-8.1 <0.001 3.6 1.4-8.8 0.007 1.6 0.8-3 0.1  2.7 1.2-5.9 0.02
>12 14.3 7.1-28.7 <0.001 10.6 4.4-26 <0.001 4.2 2.2-7.7 <0.001  3.4 1.5-8 0.005
pDDIs = potential drug-drug interactions; OR = odds ratio; CI= confidence interval.
TABLE IV - Multivariate logistic regression analysis based on exposure to >6 pDDIs and >4 Major-pDDIs
Variables
>6 pDDIs >4 Major pDDIs Excellent pDDIs Good pDDIs 
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Gender
Female - Reference - Reference
Male - - - 1.9 1.2-3 0.007 - - - 1.8 0.9-3.7 0.1
Hospital stay (Days)
<3 Reference Reference
4-6 0.8 0.5-1.3 0.3 - - - 1.2 0.7-2 0.4 - - -
>6 0.7 0.4-1.4 0.3 - - - 0.7 0.4-1.4 0.3 - - -
Prescribed medicines
<8 Reference Reference Reference Reference
9-12 4.5 2.2-9 <0.001 3.5 1.4-8.7 0.008 1.6 0.8-3 0.2  2.6 1.2-5.8 0.02
>12 16.5 7.8-34.8 <0.001 10.9 4.4-26.7 <0.001 4.4 2.3-8.5 <0.001  3.4 1.4-8 0.005
pDDIs = potential drug-drug interactions; OR = odds ratio; CI= confidence interval. 
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Wide spread interacting drug combinations
The most frequently detected pDDIs are listed in 
Table V along with their severity and documentation 
levels. Potential adverse outcomes of these interactions 





Potential adverse  
outcome




Aspirin -- Clopidogrel 189 Major Fair Increased risk of bleeding.
Aspirin -- Nitroglycerin 172 Moderate Good




Aspirin -- Spironolactone 137 Major Good
Reduced diuretic 
effectiveness, 
hyperkalemia, or possible 
nephrotoxicity.
Furosemide -- Ramipril 132 Moderate Good
Postural hypotension 
(first dose).
Digoxin -- Furosemide 112 Moderate Fair
Increased risk of 
digoxin toxicity 
(nausea, vomiting, and 
cardiac arrhythmias).
Aspirin -- Ramipril 101 Moderate Fair
Decreased Ramipril 
effectiveness.
Clopidogrel -- Enoxaparin 92 Major Fair Increased risk of bleeding.
Ramipril -- Spironolactone 80 Major Good Hyperkalemia.
Aspirin -- Bisoprolol 79 Moderate Good Increased blood pressure.
Aspirin -- Insulin 70 Moderate Fair
Increased risk of 
hypoglycemia.
(continuing)
include reduced therapeutic effectiveness, risk of 
bleeding, nephrotoxicity, hypotension, digoxin toxicity, 
electrolytes disturbance, increased blood pressure and 
hypoglycemia.
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Potential adverse  
outcome





Digoxin -- Spironolactone 61 Major Good Increased digoxin exposure.
Aspirin -- Carvedilol 46 Moderate Good Increased blood pressure.





Albuterol -- Furosemide 40 Moderate Fair
ECG changes or 
hypokalemia.
Insulin -- Ramipril 39 Moderate Fair
Increased risk of 
hypoglycemia.
Clopidogrel -- Omeprazole 35 Major Excellent
Reduction in clinical 
efficacy of Clopidogrel 
and increased risk 
for thrombosis.
Furosemide -- Morphine 31 Moderate Fair
Decreased efficacy 
of diuretics.










Digoxin -- Omeprazole 24 Moderate Good
Increased risk of digoxin 
toxicity (nausea, vomiting, 
and arrhythmias).
Bisoprolol -- Digoxin 23 Moderate Good
Increased risk of 
bradycardia and possible 
digitalis toxicity.
(continuing)
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Aspirin -- Glimepiride 21 Major Fair
Increased risk of 
hypoglycemia.
Carvedilol -- Digoxin 21 Major Fair
Increased digoxin 
concentrations; 
increased risk of 
complete heart block.
Aspirin -- Calcium 19 Moderate Fair
Decreased salicylate 
effectiveness.
Aspirin -- Ranitidine 18 Minor Excellent
Reduced salicylate plasma 
levels and decreased 
antiplatelet effect of aspirin.





Insulin -- Moxifloxacin 17 Major Fair
Changes in blood 
glucose and increased 
risk of hypoglycemia 
or hyperglycemia.
aOf total 335 drug interacting pairs, the 30 most frequent drug interacting pairs are given in this table.
bThe frequency in this column represent the number of patients exposed to the given interaction.
Clinical relevance
Table VI represents clinical findings (signs, 
symptoms and laboratory test results) and monitoring/
management guidelines (Baxter, 2010; Micromedex, 
2018; Tatro, 2009) for the most frequent (top ten) 
interacting drug pairs. Patients with the interaction 
(aspirin and furosemide), presented with shortness 
of breath (SOB), pedal edema, increased blood 
pressure (BP), orthopnea, chest pain & generalized 
edema; raised levels of blood urea nitrogen (BUN) 
and serum creatinine. In patients with the interacting 
drug pair (aspirin and clopidogrel), SOB, orthopnea, 
nausea, anemia, epistaxis and melena; reduced 
hemoglobin, raised international normalized ratio 
(INR), prothrombin time (PT) and activated partial 
thromboplastin time (APTT) were observed. In 
patients presenting with another interaction, i.e. 
aspirin and nitroglycerin, the following characteristic 
features such as hypotension, fever, dizziness, nausea/
vomiting, headache, dyspnea and vertigo; raised BUN, 
bilirubin and reduced hemoglobin were observed. 
Impaired renal function was noticed in patients with 
interactions such as aspirin + spironolactone and 
aspirin + furosemide. Moreover, an increase in BP was 
detected in patients encountered with interactions such 
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as aspirin + ramipril, aspirin + bisoprolol and ramipril 
+ spironolactone. Whereas, in patients presenting 
with interactions, i.e. aspirin + nitroglycerin and 
furosemide + ramipril, a decrease in BP was seen. 
Bleeding was observed in patients with interaction, 
clopidogrel + enoxaparin. Hyperkalemia was observed 
in patients with drug interacting pairs such as digoxin 
+ furosemide and ramipril + spironolactone. 
TABLE VI - Top ten interactions, their documentation, clinical relevance and monitoring/management guidelines
Interactions (n)
[Documentation]
Signs and symptoms (n) Laboratory investigations (n)
Monitoring, Management 
guidelines (Micromedex 2017; 










BUN: Normal (03), High (20)
Serum Creatinine: Normal 
(13), High (08)
Serum Sodium: High (02)
Serum Potassium: High (03)
Patients should be monitored 
for signs of worsening renal 
function, diuretic efficacy, 
appropriate effects on blood 
pressure and high dose 

















Patients should be monitored for 
signs and symptoms of bleeding 
and close assessment of blood 
counts. Caution is advised while 
using this combination, owing 
its increased risk of thrombotic 
events, therefore coprescription 










Hemoglobin: Low (05), High (01)
Platelets: Low (02), 
Normal (04), High (01)
BUN: Normal (03), High (14)
Bilirubin: Normal (02), High (03)
The combination may benefit the 
patients with acute myocardial 
infarction (AMI). Nevertheless, 
monitoring for an exaggerated 
response to nitroglycerin 
(headache, syncope) and 










BUN: Normal (02), High (07)
Serum Sodium: Low (02), 
Normal (02), High (01)




Patients should be monitored 
for signs of worsening renal 
function, diuretic efficacy 
and blood pressure in 
patients chronically receiving 
spironolactone and salicylates. 
The effects of interaction can 
be reversed by increasing 
the spironolactone dose.
(continuing)
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TABLE VI - Top ten interactions, their documentation, clinical relevance and monitoring/management guidelines
Interactions (n)
[Documentation]
Signs and symptoms (n) Laboratory investigations (n)
Monitoring, Management 
guidelines (Micromedex 2017; 












Serum Creatinine: Normal 
(05), High (05)
Serum Sodium: Low (01), 
Normal (03), High (01)
The patients with sodium 
depletion and hypovolemia are 
at high risk. Closely monitor 
blood pressure of the patients for 
a severe hypotensive response 
for four hours after the initial 
dose. Temporarily discontinue 
furosemide and/or the patient 
should be started at very low dose 
angiotensin converting enzyme 
(ACE) inhibitors, particularly in 
evening; monitor for hypotension, 
fluid status, and body weight 









BUN: Normal (01), High (07)
Serum Creatinine: Normal 
(03), High (04)
Serum Potassium: Normal 
(05), High (03) 
Frequent monitoring of 
serum potassium and serum 
magnesium levels.
Educate patients about 
the decrease intake of 











BUN: Normal (01), High (08)
Serum Creatinine: Normal 
(06), High (03)
Serum Sodium: Low (01), 
Normal (04), High (01)
Aspirin may result in reduced 
ramipril effectiveness. 
Patient’s blood pressure and 
hemodynamic parameters 
should be monitored. Consider 
the following option in case of 
any adverse effect; (a) aspirin 
dosage less than 100 mg per day
(b) an alternative non-
aspirin antiplatelet agent (c) 



















Prompt evaluation for signs or 
symptoms of bleeding is advised.
Additionally, if possible 
discontinue the antiplatelet agent 
prior to initiating a low molecular 
weight heparins (LMWHs).
(continuing)
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TABLE VI - Top ten interactions, their documentation, clinical relevance and monitoring/management guidelines
Interactions (n)
[Documentation]
Signs and symptoms (n) Laboratory investigations (n)
Monitoring, Management 
guidelines (Micromedex 2017; 








Serum Potassium: High (05)
Serum Creatinine: Normal 
(03), High (01)
Patients should be monitored for 
persistent elevations of serum 
potassium, especially in patients 
with renal dysfunction or diabetes 
and the elderly; which can lead to 
severe arrhythmias and death. In 
patients receiving co-prescription 
(ramipril & spironolactone); 
spironolactone may be used 25 










BUN: Normal (01), High (08)





Monitoring of blood pressure 
is advised. In heart failure, the 
beta blockers are considered to 
be narrow therapeutic index. 
Concomitant use of NSAIDs 
should generally be avoided in 
patients with heart failure.
SOB = shortness of breath; BUN = blood urea nitrogen; INR = international normalized ratio; PT = prothrombin time; APTT 
= activated partial thromboplastin time; ACE = Angiotensin converting enzyme; LMWHs = low molecular weight heparin; 
NSAIDs = Nonsteroidal anti-inflammatory drugs. 
DISCUSSION
This study presents the frequency, nature of 
pDDIs and associated clinical outcomes in LVF 
patients. The overall prevalence of pDDIs identified 
in our study is higher compared with other studies 
conducted on patients with HF (88%) (Roblek et al., 
2014; Straubhaar, Krahenbuhl, Schlienger, 2006). 
This inconsistency may be attributed to one or more 
of the following reasons: variable study design, nature 
of study subjects, drug prescribing patterns, and 
DDIs screening tools. Furthermore, 94% prevalence 
reported in our study is higher than studies conducted 
in other diseased patients, such as acquired immune 
deficiency syndrome (overall prevalence of pDDIs = 
40%) (Marzolini et al., 2010), bone marrow transplant 
(60%) (Guastaldi et al., 2011), prostate cancer (52%) 
(Jamani et al., 2016) and in different hospital wards 
like internal medicine (53%) (Ismail et al., 2013b), 
oncology (46%) (van Leeuwen et al., 2013), pediatrics 
(26%) (Ismail et al., 2013a) and psychiatry (65%) 
(Ismail et al., 2012). In the majority of hospitals 
in the developing world, the clinical pharmacy 
department and DDIs screening programs do not 
exist, which render the patients prone to irrational 
use of medicines. Lack of facilities, poor access to 
available health care facilities, and burdened health 
professionals also contribute to the underprivileged 
health management and treatment. In such situations, 
drug related problems, including pDDIs remain a major 
issue (Ismail et al., 2013b). Therefore, present results 
require proper consideration of pDDIs particularly in 
patients with LVF. Different evidence based strategies 
are recommended to manage this problem such as 
screening of medication profiles for pDDIs with the use 
of computerized based screening programs (Moura 
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et al., 2012), clinical pharmacist participation in patient 
evaluation for pDDIs (Roblek et al., 2016), laboratory 
test assessment for pDDIs related ADRs (Geerts et al., 
2009), and health professional education about pDDIs 
(Riechelmann et al., 2007).
Severity of pDDIs remains a mainstay to be 
considered for proper evaluation and management of 
pDDIs. In this study major (n=1405) and moderate-
pDDIs (n=1365) were most frequent; likewise, pDDIs 
with good (n=1349) and fair (n=1291) scientific 
evidence were most common. These findings are 
inconsistent with other studies conducted in different 
conditions and specialties or wards. A Swiss study 
reported moderate-pDDIs (65%) as most frequent 
(Straubhaar, Krahenbuhl, Schlienger, 2006). Likely, 
another study conducted in Slovenia reported 
moderate-pDDIs (92%) to be most prevalent (Roblek 
et al., 2014). In oncology, moderate-pDDIs (83%) 
(van Leeuwen et al., 2013) are more prevalent, while 
in pediatrics (26%), moderate-pDDIs and good type 
of documented evidence was reported for majority 
of pDDIs (Ismail et al., 2013a). However, in internal 
medicine, moderate-pDDIs (63%) and good (61%) 
type of documentary evidence pDDIs were mostly 
observed (Ismail et al., 2013b). Our findings suggest 
that patients with LVF are at higher risk of clinically 
significant interactions. Therefore, it is crucial for 
health care professionals to identify and classify 
pDDIs. It is important for clinical management of 
pDDIs and minimizing their risk while adopting 
prophylaxis measures for prevention.
Patients with HF usually receive polypharmacy 
for their proper management. There is a positive 
relation between number of prescribed medicines and 
risks of pDDIs (Guastaldi et al., 2011; Ismail et al., 
2012; Marzolini et al., 2010). Significant association of 
exposure to >6 pDDIs with hospital stay and number of 
prescribed medicines is in accordance with other studies 
(Ismail et al., 2017; Ismail et al., 2013a; Ismail et al., 
2013b). We have calculated odds ratio of exposure to 
>4 major-pDDIs separately. The significant relation of 
major-pDDIs with gender and prescribed medicines are 
consistent with other studies (Ismail et al., 2017; Ismail 
et al., 2013a, Ismail et al., 2013b; van Leeuwen et al., 
2013). Based on these results, patients with LVF are at 
considerable risk of major-pDDIs due to polypharmacy 
and prolonged hospital stay. Therefore, such patients 
must be screened for pDDIs, preferably through a 
Computer-based DDIs screening tool. Such screening 
is crucial before prescribing and administering drugs 
in order to identify problems in advance to prevent and 
manage them accordingly.
List of the most frequently occurring pDDIs, 
especially contraindicated, major and moderate pDDIs 
are of prime importance for physicians and pharmacists. 
It can be used for selective screening of DDIs. Patients 
with these interactions may be given special attention 
and their therapy may be closely monitored for all 
potential adverse outcomes. 
Clinical relevance specifies the potential adverse 
outcomes associated with pDDIs on the basis of patients’ 
clinical characteristics and various laboratory test 
results. This study strengthens the fact that the screening 
of medication profiles for the presence of pDDIs should 
be done. Other studies have highlighted the same issue 
(Cruciol-Souza, Thomson, 2006a; Zwart-van Rijkom 
et al., 2009). Such studies will guide the clinicians and 
other health care professionals regarding the assessment 
and management of these DDIs in LVF patients.
Following are the potential limitations of this 
study. A number of DDI resources (Pharmavista, 
Lexi-interact and Drug Interaction Facts) are available 
(Vonbach et al., 2008) and differences exist among 
the available screening tools (Kheshti, Aalipour, 
Namazi, 2016). However, we used a single software 
(Micromedex Drug-Reax), which provides complete 
and reliable information, for the screening of pDDIs. 
Furthermore, we identified some predictors that 
increase the risk for pDDIs. Further, studies can be 
designed to investigate the contribution of other 
factors such as use of a specific class of drugs, multiple 
prescribers, a specific diagnosis and type and number 
of comorbid illnesses.
CONCLUSION
This study shows high prevalence of pDDIs in LVF 
patients. Majority of interactions were of major severity, 
followed by moderate severity interactions. Patients 
of male gender and greater number of prescribed 
medicines were more exposed to major-pDDIs. List 
of most frequently identified major and moderate 
interactions will be helpful in screening medication 
therapies for pDDIs. Monitoring of all clinically relevant 
features (signs, symptoms and laboratory/diagnostic 
tests) with proper consideration of various predictors is 
recommended to prevent and manage clinical outcomes 
of these interactions.
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